Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | OXTR | P30559 | 13/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789977 | 0.90 | HTT (0.61) | HTTOXTRAVPR1AAVPR2CYP3A4 | |
| SCHEMBL791415 | 0.89 | HTT (0.54) | HTTOXTRCYP3A4CYP2C9CYP2B6 | |
| SCHEMBL790954 | 0.88 | HTT (0.51) | HTTOXTRAVPR1AAVPR2CYP3A4 | |
| SCHEMBL791061 | 0.87 | HTT (0.57) | HTTOXTRAVPR1AAVPR2CYP3A4 | |
| SCHEMBL12978170 | 0.86 | HTT (0.56) | HTTOXTRAVPR1AAVPR2CYP3A4 | |
| SCHEMBL791051 | 0.85 | HTT (0.50) | HTTOXTRAVPR1AAVPR2CYP3A4 | |
| SCHEMBL790234 | 0.85 | HTT (0.67) | HTTCYP3A4CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL791845 | 0.84 | HTT (0.54) | HTTOXTRCYP3A4CYP2C9CYP2B6 | |
| SCHEMBL791150 | 0.84 | OXTR (0.62) | HTTOXTRAVPR1ACYP3A4CYP2C9 | |
| SCHEMBL13095774 | 0.84 | HTT (0.65) | HTTCYP3A4CYP2C9CYP2B6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615917-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | BASF SE (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012034959-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | CHRM1, CHRM2, GRIN2C | HTT 1901/4885OXTR 1398/4885AVPR1A 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.